Atlas Trials

A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer

Clinical trial NCT02091960 · COMPLETED

Trial details

NCT number
NCT02091960
Sponsor
Astellas Pharma Global Development, Inc.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
HER2 AmplifiedAdvanced Breast CancerHuman Epidermal Growth Factor Receptor 2 (HER2)
Start date
2014-09-05
Primary completion
2017-02-28
Enrollment
103

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.